Literature DB >> 25363668

Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis.

G Barosi1, R P Gale2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25363668     DOI： 10.1038/leu.2014.312

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  1 in total

Review 1.  Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

Authors:  G Barosi; A Tefferi; C Besses; G Birgegard; F Cervantes; G Finazzi; H Gisslinger; M Griesshammer; C Harrison; R Hehlmann; S Hermouet; J-J Kiladjian; N Kröger; R Mesa; M F Mc Mullin; A Pardanani; F Passamonti; J Samuelsson; A M Vannucchi; A Reiter; R T Silver; S Verstovsek; G Tognoni; T Barbui
Journal:  Leukemia       Date:  2014-08-25       Impact factor: 11.528
  1 in total
  1 in total

Review 1.  Novel therapies for myelofibrosis.

Authors:  Brady L Stein; Francisco Cervantes; Francis Giles; Claire N Harrison; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-05-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.